横侧髓炎:对阿巴切的不良反应
Adeniyi A Adelakun1, Ahmad W Haddad2, Noreen Mirza2
1Internal Medicine, Saint Mary's General Hospital, Passaic, USA.
Cureus
|May 29, 2024
概括
这份病例报告强调了一种罕见的与免疫相关的横侧髓炎不良事件 (irAE),该不良事件发生在接受阿巴塞普特治疗的类风湿性关节炎患者身上. 早期检测和使用皮质类固醇的干预导致了有利的结果,强调了临床警的必要性.
科学领域:
- 类风湿病学 类风湿病学
- 神经学 神经学
- 免疫学 免疫学 免疫学
背景情况:
- 免疫疗法,如阿巴塔塞普特,是对类风湿性关节炎 (RA) 的有效疾病修饰治疗方法.
- 这些疗法可能会导致与免疫相关的不良事件 (irAEs),这些事件通常很少发生,但可能很严重.
研究的目的:
- 在接受 abatacept 的 RA 患者中报告横侧髓炎病例.
- 强调识别和管理这种罕见的irAE的重要性.
主要方法:
- 一个老年RA患者逐渐出现神经系统症状的病例报告.
- 停止服用阿巴cept并开始使用皮质类固醇治疗.
主要成果:
- 患者发病横向肌底炎,尽管RA疾病控制与 abatacept.
- 用皮质类固醇迅速治疗导致了有利的临床结果.
结论:
- 横侧髓炎是一种罕见但显著的IRAE,与RA患者的阿巴切相关.
- 临床医生应保持对不寻常的神经反应的高度怀疑指数.
- 早期诊断和干预对于管理这种不良事件至关重要.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
158
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
158
Myasthenia Gravis: Overview and Treatment
1.4K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.4K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
131
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
131
Cell-mediated Immune Responses
68.1K
Overview
68.1K
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)

